{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:03:11Z","timestamp":1789138991464,"version":"build-2803163510"},"reference-count":207,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,30]],"date-time":"2026-12-30T00:00:00Z","timestamp":1798588800000},"content-version":"am","delay-in-days":394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00-HL153696"],"award-info":[{"award-number":["R00-HL153696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpet.2025.103724","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:13:06Z","timestamp":1767082386000},"page":"103724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Half-life extension of therapeutics: Applications and mechanisms"],"prefix":"10.1016","volume":"392","author":[{"given":"Kishore","family":"Pathivada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0437","authenticated-orcid":false,"given":"Patrick M.","family":"Glassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103724_bib1","series-title":"Pharmaceutical Biotechnology: Fundamentals and Applications","first-page":"153","article-title":"Immunogenicity of therapeutic proteins","author":"Rispens","year":"2024"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antib8010003","article-title":"Pharmacologic considerations in the disposition of antibodies and antibody-drug conjugates in preclinical models and in patients","volume":"8","author":"Lucas","year":"2019","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1208\/s12248-012-9353-6","article-title":"ADME of biologics-what have we learned from small molecules?","volume":"14","author":"Prueksaritanont","year":"2012","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10989-021-10167-2","article-title":"Protease enzymes: highlights on potential of proteases as therapeutics agents","volume":"27","author":"Shankar","year":"2021","journal-title":"Int J Pept Res Ther"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2174\/1389200219666180628171531","article-title":"Metabolism of peptide drugs and strategies to improve their metabolic stability","volume":"19","author":"Yao","year":"2018","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-7364-7-22","article-title":"Update of the human and mouse SERPIN gene superfamily","volume":"7","author":"Heit","year":"2013","journal-title":"Hum Genomics"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/gb-2006-7-5-216","article-title":"An overview of the serpin superfamily","volume":"7","author":"Law","year":"2006","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1152\/nips.01461.2003","article-title":"Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier","volume":"19","author":"Haraldsson","year":"2004","journal-title":"Physiology"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.mpaic.2018.02.013","article-title":"Renal physiology: blood flow, glomerular filtration and plasma clearance","volume":"19","author":"Mangan","year":"2018","journal-title":"Anaesth Intensive Care Med"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic\u2013pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-019-04454-w","article-title":"Proteinuria-take a closer look","volume":"35","author":"Bokenkamp","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/138920009789895499","article-title":"Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies","volume":"10","author":"Lin","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jpet.2025.103724_bib13","series-title":"Pharmaceutical Biotechnology: Fundamentals and Applications","first-page":"105","article-title":"Pharmacokinetics and pharmacodynamics of therapeutic peptides and proteins","author":"Meibohm","year":"2019"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1083\/jcb.79.3.663","article-title":"Mediation of pinocytosis in cultured arterial smooth muscle and endothelial cells by platelet-derived growth factor","volume":"79","author":"Davies","year":"1978","journal-title":"J Cell Biol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1208\/s12248-012-9395-9","article-title":"Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn","volume":"14","author":"Chen","year":"2012","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1994.134","article-title":"Pharmacologic target-mediated drug disposition","volume":"56","author":"Levy","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40262-017-0590-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of the epidermal growth factor receptor inhibitor panitumumab in the treatment of colorectal cancer","volume":"57","author":"Ketzer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpet.2025.103724_bib19","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2031352a0","article-title":"A theoretical model of gamma-globulin catabolism","volume":"203","author":"Brambell","year":"1964","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","article-title":"Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn","volume":"89","author":"Israel","year":"1996","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib22","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"41","key":"10.1016\/j.jpet.2025.103724_bib23","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent advances in half-life extension strategies for therapeutic peptides and proteins","volume":"24","author":"Tan","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jpet.2025.103724_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics\u2013the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"issue":"5517","key":"10.1016\/j.jpet.2025.103724_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antib11010017","article-title":"Immune- and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies","volume":"11","author":"Baldo","year":"2022","journal-title":"Antibodies (Basel)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib29","first-page":"246","article-title":"Monoclonal antibodies as a therapeutic strategy against multidrug-resistant bacterial infections in a post-COVID-19 era","volume":"14","author":"Chen","year":"2024","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J Immunotoxicol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jaip.2018.04.007","article-title":"The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders","volume":"6","author":"Nencini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib7020019","article-title":"Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity","volume":"7","author":"Pratt","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jpet.2025.103724_bib34","first-page":"349","article-title":"Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID)","volume":"3","author":"Booth","year":"2009","journal-title":"Biologics"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJM198703053161005","article-title":"Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase","volume":"316","author":"Hershfield","year":"1987","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jpet.2025.103724_bib36","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: a review in acute lymphoblastic leukaemia","volume":"79","author":"Heo","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.10663","article-title":"Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jacc.2003.07.048","article-title":"Intravascular ultrasound molecular imaging of atheroma components in vivo","volume":"43","author":"Hamilton","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jpet.2025.103724_bib41","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200161150-00013","article-title":"Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jpet.2025.103724_bib42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200262080-00012","article-title":"Pegfilgrastim","volume":"62","author":"Curran","year":"2002","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib43","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2009-2813","article-title":"Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile","volume":"95","author":"Rasmussen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.56499\/jppres17.342_6.3.179","article-title":"A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA((R)) and ior((R))EPOCIM","volume":"6","author":"Reynaldo","year":"2018","journal-title":"J Pharm Pharmacogn Res"},{"issue":"6992","key":"10.1016\/j.jpet.2025.103724_bib45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature02580","article-title":"Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy","volume":"429","author":"Oh","year":"2004","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40259-016-0197-y","article-title":"Certolizumab Pegol: a review in inflammatory autoimmune diseases","volume":"30","author":"Deeks","year":"2016","journal-title":"BioDrugs"},{"issue":"748","key":"10.1016\/j.jpet.2025.103724_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae045","article-title":"Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism","volume":"8","author":"Hall","year":"2024","journal-title":"JBMR Plus"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib49","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/jth.14469","article-title":"Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference?","volume":"17","author":"Carcao","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib50","first-page":"141","article-title":"Extended half-life coagulation factors: a new era in the management of hemophilia patients","volume":"36","author":"Ar","year":"2019","journal-title":"Turk J Haematol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-019-01152-7","article-title":"Damoctocog Alfa Pegol: a review in haemophilia A","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.jpet.2025.103724_bib52","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1016\/S0021-9258(17)33251-9","article-title":"Phenylalanine ammonia-lyase. Induction and purification from yeast and clearance in mammals","volume":"251","author":"Fritz","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103724_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/1177392819857089","article-title":"A comprehensive review of Pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria","volume":"13","author":"Hydery","year":"2019","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.jpet.2025.103724_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113959","article-title":"Programmable chronogenetic gene circuits for self-regulated circadian delivery of biologic drugs","volume":"385","author":"Cimino","year":"2025","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/cei.13420","article-title":"Comparison of elapegademase and pegademase in ADA-deficient patients and mice","volume":"200","author":"Murguia-Favela","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/gels9020169","article-title":"Hydrogel encapsulation of genome-engineered stem cells for long-term self-regulating anti-cytokine therapy","volume":"9","author":"Collins","year":"2023","journal-title":"Gels"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.jpet.2025.103724_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib59","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/imcb.12646","article-title":"Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcgammaRIIb binding and retention of super-agonist activity","volume":"101","author":"Chenoweth","year":"2023","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib60","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00262-020-02723-4","article-title":"Patients with gastrointestinal irritability after TGN1412-induced cytokine storm displayed selective expansion of gut-homing alphabeta and gammadeltaT cells","volume":"70","author":"McCarthy","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib61","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0005-2744(77)90096-1","article-title":"alpha-galactosidase A from human placenta. Stability and subunit size","volume":"484","author":"Mayes","year":"1977","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib62","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00262-020-02725-2","article-title":"Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm","volume":"70","author":"Panoskaltsis","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"10.1016\/j.jpet.2025.103724_bib63","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40265-023-01948-8","article-title":"Avacincaptad Pegol: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib64","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00262-020-02702-9","article-title":"Myelopoiesis of acute inflammation: lessons from TGN1412-induced cytokine storm","volume":"70","author":"Panoskaltsis","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib65","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","article-title":"Hypoparathyroidism: diagnosis, management and emerging therapies","volume":"21","author":"Khan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib66","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/eji.201847924","article-title":"Human Fcgamma receptors compete for TGN1412 binding that determines the antibody\u2019s effector function","volume":"49","author":"Dudek","year":"2019","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib68","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.jpet.2025.103724_bib69","first-page":"482","article-title":"Romiplostim (Nplate), a treatment option for immune (idiopathic) thrombocytopenic purpura","volume":"34","author":"Hubulashvili","year":"2009","journal-title":"P T"},{"key":"10.1016\/j.jpet.2025.103724_bib70","first-page":"1","article-title":"Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)","volume":"3","author":"Gillespie","year":"2010","journal-title":"J Inflamm Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2012.04.020","article-title":"Aflibercept for age-related macular degeneration: a game-changer or quiet addition?","volume":"154","author":"Browning","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.1Q537","article-title":"Belatacept: a new biologic and its role in kidney transplantation","volume":"46","author":"Su","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1060028013506562","article-title":"Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer","volume":"48","author":"Perkins","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib74","first-page":"357","article-title":"Dulaglutide (Trulicity): the third once-weekly GLP-1 Agonist","volume":"41","author":"Smith","year":"2016","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib76","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-017-0778-1","article-title":"Eftrenonacog alfa: a review in haemophilia B","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40265-019-01251-5","article-title":"Luspatercept: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jpet.2025.103724_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.taap.2019.03.020","article-title":"Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models","volume":"372","author":"Yan","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib79","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40265-023-01866-9","article-title":"Efanesoctocog alfa: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17425255.2024.2409931","article-title":"Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A","volume":"21","author":"Yada","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbrc.2018.05.125","article-title":"Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog","volume":"502","author":"Iwata","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib82","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-024-02058-9","article-title":"Sotatercept: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib83","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","article-title":"Nogapendekin alfa inbakicept: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/diseases6020041","article-title":"Revisiting CD28 superagonist TGN1412 as potential therapeutic for pediatric B cell leukemia: a review","volume":"6","author":"Brown","year":"2018","journal-title":"Diseases"},{"issue":"17","key":"10.1016\/j.jpet.2025.103724_bib85","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2165\/11470200-000000000-00000","article-title":"Insulin detemir: a review of its use in the management of diabetes mellitus","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.jpet.2025.103724_bib86","first-page":"498","article-title":"Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes","volume":"35","author":"Jackson","year":"2010","journal-title":"P T"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib87","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40265-015-0370-5","article-title":"Albiglutide: a review of its use in patients with type 2 diabetes mellitus","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17446651.2016.1113129","article-title":"Insulin degludec\/liraglutide (IDegLira) for the treatment of type 2 diabetes","volume":"11","author":"Gough","year":"2016","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1060028017689878","article-title":"Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management","volume":"51","author":"McCarty","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40265-016-0679-8","article-title":"Coagulation factor IX (recombinant), albumin fusion protein (albutrepenonacog alfa; idelvion((R))): a review of its use in haemophilia B","volume":"77","author":"Lyseng-Williamson","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib91","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jpet.2025.103724_bib92","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/DDDT.S315172","article-title":"Developments in the management of growth hormone deficiency: clinical utility of somapacitan","volume":"18","author":"Miller","year":"2024","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40259-024-00648-3","article-title":"Next-generation anti-TNFalpha agents: the example of ozoralizumab","volume":"38","author":"Tsumoto","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.jpet.2025.103724_bib212","series-title":"Skytrofa (lonapegsomatropin-tcgd) [package insert]","year":"2021"},{"key":"10.1016\/j.jpet.2025.103724_bib213","series-title":"Syfovre (pegcetacophan injection) [package insert]","year":"2024"},{"key":"10.1016\/j.jpet.2025.103724_bib214","series-title":"Besremi (ropeginterferon alfa-2b-njft) [package insert]","year":"2021"},{"key":"10.1016\/j.jpet.2025.103724_bib94","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.crfs.2022.10.031","article-title":"Advances in the stability challenges of bioactive peptides and improvement strategies","volume":"5","author":"Pei","year":"2022","journal-title":"Curr Res Food Sci"},{"issue":"8","key":"10.1016\/j.jpet.2025.103724_bib95","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1021\/acs.jmedchem.2c00094","article-title":"On the utility of chemical strategies to improve peptide gut stability","volume":"65","author":"Kremsmayr","year":"2022","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib96","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/abbs\/gmx091","article-title":"D-amino acid substitution enhances the stability of antimicrobial peptide polybia-CP","volume":"49","author":"Jia","year":"2017","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.jpet.2025.103724_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.563030","article-title":"D- and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics","volume":"11","author":"Lu","year":"2020","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.jpet.2025.103724_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3337","article-title":"N-terminal acetylation of antimicrobial peptide L163 improves its stability against protease degradation","volume":"27","author":"Li","year":"2021","journal-title":"J Pept Sci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib99","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14740338.2019.1573985","article-title":"Making a case for the right \u2018-ase\u2019 in acute ischemic stroke: alteplase, tenecteplase, and reteplase","volume":"18","author":"Chester","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"10.1016\/j.jpet.2025.103724_bib100","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpet.2025.103724_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108750","article-title":"Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment","volume":"113","author":"AlQahtani","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib102","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","article-title":"Strategies for extending the half-life of biotherapeutics: successes and complications","volume":"25","author":"Binder","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib103","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10600","article-title":"PEGylated therapeutics in the clinic","volume":"9","author":"Gao","year":"2024","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.jpet.2025.103724_bib105","article-title":"Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib106","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expr Purif"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib107","doi-asserted-by":"crossref","first-page":"25831","DOI":"10.3390\/ijms161025831","article-title":"Site-specific PEGylation of therapeutic proteins","volume":"16","author":"Dozier","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib108","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)","volume":"10","author":"Molineux","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib109","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/bc400435u","article-title":"Comparison of site-specific PEGylations of the N-terminus of interferon beta-1b: selectivity, efficiency, and in vivo\/vitro activity","volume":"25","author":"Zhou","year":"2014","journal-title":"Bioconjug Chem"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib110","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/bc300265n","article-title":"Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects","volume":"23","author":"Kim","year":"2012","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib111","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1248\/bpb.b19-00612","article-title":"C-terminal cysteine PEGylation of adalimumab fab with an engineered interchain SS bond","volume":"43","author":"Nakamura","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib112","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/bc500357n","article-title":"Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy","volume":"25","author":"Tumey","year":"2014","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.jpet.2025.103724_bib113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2018.07.002","article-title":"Minireview: addressing the retro-Michael instability of maleimide bioconjugates","volume":"30","author":"Szijj","year":"2018","journal-title":"Drug Discov Today Technol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"68","key":"10.1016\/j.jpet.2025.103724_bib115","doi-asserted-by":"crossref","first-page":"15867","DOI":"10.1002\/chem.202003951","article-title":"Improving the stability of maleimide-thiol conjugation for drug targeting","volume":"26","author":"Lahnsteiner","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.jpet.2025.103724_bib116","series-title":"Polymer-Protein Conjugates","first-page":"155","article-title":"8\u2014PEGylation of human coagulation factor VIII and other plasma proteins","author":"Siekmann","year":"2020"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib117","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","article-title":"Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"99","author":"Solms","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1248\/bpb.b13-00661","article-title":"Discussion about several potential drawbacks of PEGylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jpet.2025.103724_bib119","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.jpet.2025.103724_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119313","article-title":"Novel XTENylated AWRK6 analog with hypoglycemic activity, and anti-HSV-2 potential in combination with double shRNA","volume":"274","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"issue":"12","key":"10.1016\/j.jpet.2025.103724_bib121","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"44","key":"10.1016\/j.jpet.2025.103724_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202101633","article-title":"Protein engineering strategies for improved pharmacokinetics","volume":"31","author":"Rondon","year":"2021","journal-title":"Adv Funct Mater"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib123","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s12010-023-04522-w","article-title":"Expression, purification, and biological evaluation of XTEN-GCSF in a neutropenic rat model","volume":"196","author":"Nikravesh","year":"2024","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.jpet.2025.103724_bib124","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"Podust","year":"2016","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/ijms22010124","article-title":"PASylated thymosin alpha1: a long-acting immunostimulatory peptide for applications in oncology and virology","volume":"22","author":"Binder","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib126","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/mp5007147","article-title":"PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy","volume":"12","author":"Morath","year":"2015","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425247.2023.2297937","article-title":"Polypeptides as alternatives to PEGylation of therapeutic agents","volume":"21","author":"Chen","year":"2024","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jpet.2025.103724_bib128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-bioeng-092419-061127","article-title":"Elastin-like polypeptides for biomedical applications","volume":"22","author":"Varanko","year":"2020","journal-title":"Annu Rev Biomed Eng"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1467-7652.2010.00523.x","article-title":"ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock","volume":"9","author":"Conrad","year":"2011","journal-title":"Plant Biotechnol J"},{"issue":"6207","key":"10.1016\/j.jpet.2025.103724_bib130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/337525a0","article-title":"Designing CD4 immunoadhesins for AIDS therapy","volume":"337","author":"Capon","year":"1989","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/imt-2017-0155","article-title":"Etanercept for the treatment of rheumatoid arthritis","volume":"10","author":"Zhao","year":"2018","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib132","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib133","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/17512433.2016.1141046","article-title":"Dulaglutide (LY-2189265) for the treatment of type 2 diabetes","volume":"9","author":"Scheen","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103724_bib134","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol Cell Ther"},{"issue":"34","key":"10.1016\/j.jpet.2025.103724_bib135","doi-asserted-by":"crossref","first-page":"24544","DOI":"10.1016\/S0021-9258(18)35799-5","article-title":"Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism","volume":"267","author":"Schnitzer","year":"1992","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib136","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1016\/S0021-9258(18)53212-9","article-title":"High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors","volume":"268","author":"Schnitzer","year":"1993","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib137","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.molpharmaceut.5b00605","article-title":"Neonatal Fc receptor binding tolerance toward the covalent conjugation of payloads to cysteine 34 of human albumin variants","volume":"13","author":"Petersen","year":"2016","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib138","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/pharmaceutics12040364","article-title":"Recombinant peptide production platform coupled with site-specific albumin conjugation enables a convenient production of long-acting therapeutic peptide","volume":"12","author":"Bak","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpet.2025.103724_bib139","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2015.04.004","article-title":"Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo","volume":"207","author":"Lim","year":"2015","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib140","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1053\/j.gastro.2008.01.017","article-title":"An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis","volume":"134","author":"Baggio","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jpet.2025.103724_bib141","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/13543784.2021.2008906","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects","volume":"30","author":"Ding","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"38","key":"10.1016\/j.jpet.2025.103724_bib142","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","article-title":"Albumin binding as a general strategy for improving the pharmacokinetics of proteins","volume":"277","author":"Dennis","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103724_bib143","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16092","article-title":"Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides","volume":"8","author":"Zorzi","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib144","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1039\/C9MD00018F","article-title":"Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics","volume":"10","author":"Zorzi","year":"2019","journal-title":"Medchemcomm"},{"issue":"7","key":"10.1016\/j.jpet.2025.103724_bib145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/acsmedchemlett.8b00226","article-title":"Chemical strategies for half-life extension of biopharmaceuticals: lipidation and its alternatives","volume":"9","author":"Bech","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib146","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/dom.12052","article-title":"Insulin degludec: overview of a novel ultra long-acting basal insulin","volume":"15","author":"Gough","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jpet.2025.103724_bib147","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jpet.2025.103724_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173650","article-title":"Albumin-binding domain extends half-life of glucagon-like peptide-1","volume":"890","author":"Tan","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib149","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/protein\/gzm061","article-title":"A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G","volume":"20","author":"Stork","year":"2007","journal-title":"Protein Eng Des Sel"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib150","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41598-021-04560-6","article-title":"Extension of human GCSF serum half-life by the fusion of albumin binding domain","volume":"12","author":"Nikravesh","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib151","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgaf042","article-title":"Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life","volume":"4","author":"Mester","year":"2025","journal-title":"PNAS Nexus"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib152","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1893888","article-title":"Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo","volume":"13","author":"Mester","year":"2021","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib153","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"issue":"15\u201316","key":"10.1016\/j.jpet.2025.103724_bib154","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","article-title":"DARPins: a new generation of protein therapeutics","volume":"13","author":"Stumpp","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jpet.2025.103724_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121043","article-title":"Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold","volume":"607","author":"Tan","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jpet.2025.103724_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106422","article-title":"Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo","volume":"185","author":"Xia","year":"2023","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.jpet.2025.103724_bib157","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.slasd.2023.08.008","article-title":"Nanobodies: a game-changer in cell-mediated immunotherapy for cancer","volume":"28","author":"Mustafa","year":"2023","journal-title":"SLAS Discov"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib158","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1535-7163.MCT-11-0891","article-title":"Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy","volume":"11","author":"Vosjan","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.jpet.2025.103724_bib159","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","article-title":"Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular nanobody technology","volume":"7","author":"Tijink","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib160","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.21827","article-title":"Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis","volume":"54","author":"Coppieters","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib161","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1021\/acs.bioconjchem.0c00003","article-title":"Molecularly engineered nanobodies for tunable pharmacokinetics and drug delivery","volume":"31","author":"Glassman","year":"2020","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib162","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/clpt.2014.187","article-title":"GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans\u2013PK\/PD and safety","volume":"96","author":"O\u2019Connor-Semmes","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib163","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/protein\/gzm067","article-title":"Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs","volume":"21","author":"Holt","year":"2008","journal-title":"Protein Eng Des Sel"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib164","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/protein\/gzp091","article-title":"Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon","volume":"23","author":"Walker","year":"2010","journal-title":"Protein Eng Des Sel"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103738","article-title":"Human serum albumin binders: a piggyback ride for long-acting therapeutics","volume":"28","author":"Ullah","year":"2023","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib166","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40005-016-0250-3","article-title":"Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation","volume":"46","author":"Lee","year":"2016","journal-title":"J Pharm Investig"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib167","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib168","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"issue":"17","key":"10.1016\/j.jpet.2025.103724_bib169","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.3390\/ijms23179604","article-title":"Monoclonal antibody engineering and design to modulate FcRn activities: a comprehensive review","volume":"23","author":"Ramdani","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103724_bib170","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.jpet.2025.103724_bib171","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"10.1016\/j.jpet.2025.103724_bib172","doi-asserted-by":"crossref","first-page":"13492","DOI":"10.1074\/jbc.M114.549832","article-title":"Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding","volume":"289","author":"Andersen","year":"2014","journal-title":"J Biol Chem"},{"issue":"565","key":"10.1016\/j.jpet.2025.103724_bib173","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0580","article-title":"An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics","volume":"12","author":"Bern","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib174","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425241003610633","article-title":"Drug delivery by red blood cells: vascular carriers designed by mother nature","volume":"7","author":"Muzykantov","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2141.2000.02059.x","article-title":"In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase","volume":"109","author":"Bax","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103724_bib176","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00195932","article-title":"Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells","volume":"49","author":"Kravtzoff","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib177","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/ijms24010475","article-title":"Half-life extension and biodistribution modulation of biotherapeutics via red blood cell hitch-hiking with novel anti-band 3 single-domain antibodies","volume":"24","author":"Nguyen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib178","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/jpet.109.159194","article-title":"Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis","volume":"332","author":"Zaitsev","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"25","key":"10.1016\/j.jpet.2025.103724_bib179","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1182\/blood-2010-01-261610","article-title":"Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation","volume":"115","author":"Zaitsev","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib180","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1096\/fj.201600912R","article-title":"Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury","volume":"31","author":"Carnemolla","year":"2017","journal-title":"FASEB J"},{"issue":"20","key":"10.1016\/j.jpet.2025.103724_bib181","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1182\/blood-2011-12-398149","article-title":"Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis","volume":"119","author":"Zaitsev","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jpet.2025.103724_bib182","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.4c00522","article-title":"Biomechanical and functional features of the carrier erythrocytes prolonging circulation time of biotherapeutic targeted to glycophorin A","volume":"36","author":"Peshkova","year":"2025","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib183","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/bloodadvances.2017011734","article-title":"Biocompatible coupling of therapeutic fusion proteins to human erythrocytes","volume":"2","author":"Villa","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jpet.2025.103724_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101674","article-title":"A low-immunogenic genetically-fusible zwitterionic polypeptide","volume":"47","author":"McMullen","year":"2022","journal-title":"Nano Today"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib185","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.3390\/molecules27103272","article-title":"GlycoTAIL and FlexiTAIL as half-life extension modules for recombinant antibody fragments","volume":"27","author":"Seifert","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.jpet.2025.103724_bib186","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11206890-000000000-00000","article-title":"Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction","volume":"25","author":"Croxtall","year":"2011","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib187","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/cpdd.1434","article-title":"A randomized, cross-over study investigating the comparability of somatrogon-ghla in 2 different drug product presentations","volume":"13","author":"Manners","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jpet.2025.103724_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122031","article-title":"D-VITylation: harnessing the biology of vitamin D to improve the pharmacokinetic properties of peptides and small proteins","volume":"624","author":"Hall","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jpet.2025.103724_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124382","article-title":"Development of a predictive algorithm for the efficacy of half-life extension strategies","volume":"660","author":"Glassman","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jpet.2025.103724_bib190","series-title":"Alprolix (coagulation factor IX [recombinant], Fc fusion protein). Package insert. Bioverativ Therapeutics","year":"2020"},{"key":"10.1016\/j.jpet.2025.103724_bib191","series-title":"Idelvion (coagulation factor IX [recombinant], albumin fusion). Package insert","year":"2023"},{"key":"10.1016\/j.jpet.2025.103724_bib192","series-title":"Rebinyn (coagulation factor IX [recombinant], GlycoPEGylated). Package insert","year":"2017"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2025.103724_bib195","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"Tiede","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jpet.2025.103724_bib201","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib202","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.3390\/ijms24108584","article-title":"Plasma clearance of coagulation factor VIII and extension of its half-life for the therapy of hemophilia A: a critical review of the current state of research and practice","volume":"24","author":"Sarafanov","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.jpet.2025.103724_bib203","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jpet.2025.103724_bib204","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.1074\/jbc.M111.319764","article-title":"Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9","volume":"287","author":"Chaparro-Riggers","year":"2012","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103724_bib205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.117.246900","article-title":"\u201cCatch-and-release\u201d anti-carcinoembryonic antigen monoclonal antibody leads to greater plasma and tumor exposure in a mouse model of colorectal cancer","volume":"366","author":"Engler","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib206","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103724_bib207","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.bbapap.2014.08.003","article-title":"pH-dependent antigen-binding antibodies as a novel therapeutic modality","volume":"1844","author":"Igawa","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.jpet.2025.103724_bib208","article-title":"Synthetic gene circuits for regulation of next-generation cell-based therapeutics","volume":"11","author":"Teixeira","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103724_bib209","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1476-5381.2010.00922.x","article-title":"Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells","volume":"161","author":"Eastwood","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"9547","key":"10.1016\/j.jpet.2025.103724_bib210","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(06)69651-7","article-title":"Lessons from TGN1412","volume":"368","author":"Hanke","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jpet.2025.103724_bib211","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:04:12Z","timestamp":1777421052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":207,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022356525402377"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103724","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Half-life extension of therapeutics: Applications and mechanisms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103724"}}